Llwytho...
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
PURPOSE: To evaluate dabrafenib, a selective BRAF inhibitor, combined with trametinib, a selective MEK inhibitor, in patients with BRAF V600–mutant metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: A total of 43 patients with BRAF V600–mutant mCRC were treated with dabrafenib (150 mg twice...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | J Clin Oncol |
|---|---|
| Prif Awduron: | , , , , , , , , , , , , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
American Society of Clinical Oncology
2015
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4669588/ https://ncbi.nlm.nih.gov/pubmed/26392102 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.63.2471 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|